SCOTTSDALE, AZ--(Marketwire - March 26, 2009) - ImmuneRegen® BioSciences, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), will present its current findings on Homspera®, the company’s immune system-enhancing preclinical drug candidate, at the 2009 BIO International Convention (BIO 2009) May 18-21 in Atlanta, Ga.
ImmuneRegen is one of many leading Arizona life science organizations partnering with the Arizona Department of Commerce to represent the state inside the convention’s Arizona Pavilion at the Georgia World Congress Center in Atlanta, Ga. The Arizona contingent will join more than 20,000 representatives from leading biotech, pharmaceutical and device companies from 70 countries around the world for educational, networking and business development activities.
“This opportunity will enable ImmuneRegen to present its current findings on Homspera to a broad array of global life science executives and product development representatives,” said Michael Wilhelm, ImmuneRegen chief executive officer, adding “the drug candidate has shown the ability to stimulate adult human stem cells of the blood-forming system to increase circulating levels of white blood cells. This effect is likely to result in the survival benefit seen in animals administered Homspera following exposure to otherwise lethal doses of penetrating radiation.”
It may also be partially responsible for the ability of Homspera to effectively enhance immune responses when administered with certain vaccines (vaccine adjuvant activity), to decrease both virus levels and the effects of viral infection in animals exposed to influenza, including the potentially pandemic H5N1 avian flu, and to enhance wound healing, with implications for potential cosmeceutical applications.
ImmuneRegen continues to advance its studies in these fields, collaborating with leading academic and industrial research organizations, while pursuing outlicensing opportunities and partnerships.
In addition, ImmuneRegen will be among a selection of companies profiled in a special biotech issue of Arizona Tech Connect Magazine being produced for distribution at BIO 2009 and for advanced emailing to 300 media representatives registered to attend BIO 2009.
About ImmuneRegen BioSciences Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona-based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.
Statements about ImmuneRegen’s future expectations, including statements about the potential use and scientific results for ImmuneRegen’s drug candidates, science and technology, and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen’s business, are subject to various risks and uncertainties. ImmuneRegen’s actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen’s periodic report on Form 10-Q for the three months ended September 30, 2008 as filed on November 13, 2008, and, on Form 10-KSB for the year ended December 31, 2007 as filed on March 31, 2008 and as amended on Form 10-KSB/A, Amendment No. 1 filed on September 25, 2008 with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen’s proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
Contact:
John Fermanis
480-922-3926
Email Contact
